MSR119 Assessing the Impact of PD-L1 and BRAF Biomarkers on Long-Term Survivorship (LTS) Rates Among Treatment-Naive Advanced Melanoma Patients Receiving Immune Checkpoint Inhibitors (ICIs)
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.1271
https://www.valueinhealthjournal.com/article/S1098-3015(25)01396-8/fulltext
Title :
MSR119 Assessing the Impact of PD-L1 and BRAF Biomarkers on Long-Term Survivorship (LTS) Rates Among Treatment-Naive Advanced Melanoma Patients Receiving Immune Checkpoint Inhibitors (ICIs)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)01396-8&doi=10.1016/j.jval.2025.04.1271
First page :
Section Title :
Open access? :
No
Section Order :
10966